BioNexus Gene Lab Corp

BioNexus Gene Lab Corp

NNASDAQ:BGLC
0.82
USD
+0.00
(-0.12%)
-1.20EPS
4.71MMarket Cap

Total Valuation

USD

As of June 30, 2026, BioNexus Gene Lab Corp carries a market capitalization of 4.71M, placing it among publicly traded companies globally. Its enterprise value stands at 1.39M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap4.71M
Enterprise Value1.39M

Share Statistics

As of June 30, 2026, BioNexus Gene Lab Corp has 2.42M shares outstanding.

Shares Outstanding2.42M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 1.34, and the price-to-book ratio stands at 0.61.

PS Ratio1.34
PB Ratio0.61
P/TBV Ratio0.61
P/FCF Ratio-4.92
P/OCF Ratio-4.96

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 0.44 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.39M versus a market cap of 4.71M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales0.44

Financial Position

As of June 30, 2026, BioNexus Gene Lab Corp maintains a current ratio of 6.08, meaning it holds 6.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.55, indicating elevated leverage, while an interest coverage ratio of -140.96 demonstrates limited ability to service its debt obligations.

Current Ratio6.08
Quick Ratio4.56
Debt / Equity2.55
Debt / EBITDA-0.08
Interest Coverage-140.96

Financial Efficiency

USD

Over the twelve months ended June 30, 2026, BioNexus Gene Lab Corp posted a negative return on equity (ROE) of -33.66, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -28.38, reflecting losses generated across the asset base. The company generates approximately 160,337.49 in revenue per employee across its workforce of 19.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.93 indicates how many times BioNexus Gene Lab Corp sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-33.66
Return on Assets (ROA)-28.38
Revenue Per Employee160,337.49
Employee Count19.50
Inventory Turnover2.93

Stock Price Statistics

USD

As of the close on November 16, 2026, BioNexus Gene Lab Corp's stock has declined approximately 81.90% over the past 52 weeks. The 50-day moving average sits at 1.21, while the 200-day moving average is 1.85.

52-Week Price Change-81.90%
50-Day Moving Average1.21
200-Day Moving Average1.85

Income Statement

USD

Over the twelve months ended June 30, 2026, BioNexus Gene Lab Corp generated 3.13M in revenue and converted that into -2.58M in net income, yielding earnings per share of -1.20. EBITDA reached -2.38M, while operating income came in at -2.73M.

Revenue3.13M
Gross Profit385,894.00
Operating Income-2.73M
Pretax Income-2.58M
Net Income-2.58M
EBITDA-2.38M
EBIT-2.56M
Earnings Per Share (EPS)-1.20

Balance Sheet

USD

As of June 30, 2026, BioNexus Gene Lab Corp holds 3.52M in cash and equivalents against 198,585.00 in total debt, resulting in a net debt position of -1.23M. Total book value stands at 7.78M, with working capital of 4.13M providing operational flexibility.

Cash & Cash Equivalents3.52M
Total Debt198,585.00
Net Debt-1.23M
Equity (Book Value)7.78M
Book Value Per Share3.22
Working Capital4.13M

Cash Flow

USD

BioNexus Gene Lab Corp produced -846,565.00 in operating cash flow over the twelve months ended June 30, 2026. After subtracting -7,035.00 in capital expenditures, free cash flow totaled -853,600.00 - equivalent to -0.40 per share.

Operating Cash Flow-846,565.00
Capital Expenditures-7,035.00
Free Cash Flow-853,600.00
FCF Per Share-0.40

Margins

Over the twelve months ended June 30, 2026, BioNexus Gene Lab Corp posted a gross margin of 12.34, reflecting its pricing power and cost economics. The operating margin of -87.18 and net profit margin of -82.36 provide insight into operational efficiency.

Gross Margin12.34
Operating Margin-87.18
Pretax Margin-82.36
Profit Margin-82.36
EBITDA Margin-76.17

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -20.33: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -7.94, meaning BioNexus Gene Lab Corp raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-7.94
FCF Yield-20.33

Stock Splits

BioNexus Gene Lab Corp's most recent stock split took place on April 7, 2025 with a 10:1 split ratio.

Last Split Date4/7/2025
Split Ratio10:1

Scores

As of June 30, 2026, BioNexus Gene Lab Corp has an Altman Z-Score of 1.71, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.71